• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Mendus AB (publ) repurchases outstanding warrants from Fenja

IMMUPressemeddelelse10.06.2026, 17.30
Discuss

Mendus AB (publ) (“Mendus” or the “Company”) has today repurchased 1,935,605 warrants from Fenja Capital II A/S (“Fenja”). The repurchase price amounts to approximately SEK 3.7 million.

On 18 November 2025, the Company entered into a loan facility with Fenja of, in total, SEK 50 million (the “Loan Facility”). The Loan Facility is split into two tranches, of which the first tranche was drawn down on 30 January 2026. In connection with the drawdown of the first tranche, Mendus resolved on a directed issue of 1,935,605 warrants of series 2025/2030 (the “Warrants”) to Fenja in accordance with the terms and conditions of the Loan Facility. The subscription price for the exercise of the warrants is SEK 7 per share.

The Loan Facility includes a call option for Mendus to repurchase the Warrants, which Mendus has now decided to exercise to repurchase all 1,935,605 Warrants. The repurchase price amounts to approximately SEK 3.7million, corresponding to the market value of the Warrants as determined by an independent valuation institute appointed by Mendus. Following the repurchase, Mendus will cancel the Warrants.

For further information regarding the Loan Facility and the issue of Warrants, please refer to the press releases issued on 18 November 2025, 16 December 2025, and 30 January 2026.

For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

Attachments
Mendus AB (publ) repurchases outstanding warrants from Fenja